Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: Report of a case series with 144 patients

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 6, 2011, Pages 730-733

  Sanchez Moya A I ^a   Dauden, E ^b  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

adalimumab; biological therapy; etanercep; infliximab; psoriasis; tuberculosis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ISONIAZID; TUBERCULIN;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; LATENT TUBERCULOSIS INFECTION; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; SPAIN; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 79955889311     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03836.x     Document Type: Article

References (20)

1. Hernandez C, Cetner AS, Jordan JE,. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008; 59: 363-379.
2. Gamo R, Lopez-Estebaranz JL,. Terapia biolõgica y psoriasis. Actas Dermosifiliogr 2006; 97: 1-17.
3. Ehlers S,. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2004; 38: 1261-1265.
4. Carmona L, Gomez-Reino J, Rodrıguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 56: 1766-1772. (Pubitemid 40852885)
5. World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing. WHO Report 2005. World Health Organization, Geneva, Switzerland, 2005, pp. 1-247.
6. Ruiz-Manzano J, Blanquer R, Calpe JL, et al. Diagnosis and treatment of tuberculosis. Arch Bronconeumol 2008; 44: 551-566.
7. Puig L, Carrascosa JM, Daudén E, et al. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr 2009; 100: 386-413.
8. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin test: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-1204. (Pubitemid 44713473)
9. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-Î release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800.
10. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
11. Tsiouri G, Gaitanis G, Kiorpelidou D, et al. Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis. Dermatology 2009; 219: 119-125.
12. Vidal R,. Tuberculosis y micobacteriosis. Med Respir 2006; 51: 899-923.
13. Miret-Cuadras P, Pina-Gutiérrez JM, Juncosa S,. Tuberculin reactivity in bacillus Calmette-Guérin vaccinated subjects. Tuberc Lung Dis 1996; 77: 52-58. (Pubitemid 26066611)
14. Moreno S, Blazquez R, Novoa A, et al. The effect of BCG vaccination on tuberculin reactivity and the booster effect among hospital employees. Arch Intern Med 2001; 161: 1760-1765. (Pubitemid 32679551)
15. Iñigo J, Arce A, Palenque E, et al. Decreased tuberculosis incidence and declining clustered case rates, Madrid. Emerg Infect Dis 2008; 14: 1641-1643.
16. Pai M, Kalantri S, Dhea K,. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diag 2006; 6: 413-422. (Pubitemid 44174345)
17. Menzies D, Pai M, Comstock G,. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354. (Pubitemid 351650594)
18. Manadan AM, Joyce K, Sequeira W, et al. Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol 2007; 25: 743-745. (Pubitemid 350284848)
19. Gomez-Reino JJ, Carmona L, Angel Descalzo M,. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761. (Pubitemid 46932080)
20. Perlmutter A, Mittal A, Menter A,. Tuberculosis and tumor necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160: 8-15.